1. Home
  2. Labeler Index
  3. Biocon Pharma Inc
  4. 70377-022
  5. Product Images: Pemetrexed

Product Images Pemetrexed

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Pemetrexed NDC 70377-022 by Biocon Pharma Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Structural Formula - Structure

Structural Formula - Structure

Carton label.jpg - cartonlabel

Carton label.jpg - cartonlabel

This is a description of a pharmaceutical product called Pemetrexed Injection, USP. It is a medication used for intravenous use only and is available in single-dose vials. The package contains a vial with 1000mg/vi dosage. A valid prescription is required to purchase the product.*

Figure 1 - fig 1

Figure 1 - fig 1

Figure 2 - fig 2

Figure 2 - fig 2

This is a table displaying survival probability data for patients treated with Pemetrexed + Cisplatin (AC) versus Gemcitabine + Cisplatin (GC). The table shows the number of patients at risk, survival time in months, and corresponding values at different intervals.*

Figure 3 - fig 3

Figure 3 - fig 3

This appears to be a chart or graph displaying data related to survival rates of patients based on different treatment options. The treatment options include "Pemetrexed + Cisplatin" and "Gemcitabine + Cisplatin." The data appears to include survival probabilities and the number of patients at risk over a range of time intervals expressed in months.*

Figure 4 - fig 4

Figure 4 - fig 4

This is a survival probability chart comparing the outcome of two chemotherapy treatments: Pemetrexed + Cisplatin (AC) and Gemcitabine + Cisplatin (GC). The x-axis represents the number of months and the y-axis represents the probability of survival. The chart shows the number of patients still alive at certain time intervals and the number of patients who did not survive the treatment.*

Figure 5 - fig 5

Figure 5 - fig 5

Figure 6 - fig 6

Figure 6 - fig 6

This appears to be a table displaying survival probability and patients at risk for two groups, one that received Pemetrexed and the other a placebo. The table also shows the survival time in months for the patients. However, the formatting of the data is unclear and incomplete, and it is difficult to provide a more detailed analysis without additional context or information.*

Figure 7 - fig 7

Figure 7 - fig 7

This is a survival curve showing the probability of survival for patients grouped by treatment with Pemetrexed or Placebo. The number of patients at risk is listed for each treatment group at various time points. However, the graph is not readable and the text seems incomplete, so additional information is not available.*

Figure 8 - fig 8

Figure 8 - fig 8

This is a survival probability chart for patients who were administered Pemetrexed and Placebo. The chart shows the survival time in months and the number of patients at each time interval. The patients at risk are also shown for each interval.*

Figure 9 - fig 9

Figure 9 - fig 9

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.